Scientists at Exopharm have collaborated with Associate Professor Jason Howitt and his research team at Swinburne University of Technology to probe the molecular processes that occur with aging. NAD+ (nicotinamide adenine dinucleotide), an essential metabolite for energy metabolism, declines with age, however extracellular vesicles (EVs) released by the body during exercise can boost NAD+ levels […]
We are pleased to announce that our Expert View article titled “Extracellular Vesicle Engineering: Optimising Nature’s Non-Immunogenic, Drug Delivery Platform” has been published in ONdrugDelivery. You can check out this Expert View article from Exopharm’s Research and Innovation Manager, Dr Anna Cifuentes-Rius here . Dr Cifuentes-Rius discusses how to take advantage of EV’s capacity to […]
With a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals and foundational patents, Exopharm is poised to become an essential part of the modern medicine ecosystem. As the only listed exosome company on the ASX, and one of a small number of exosome companies listed globally, Australian biopharma Exopharm (ASX:EX1) […]
Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial services are designed to seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm’s facilities in Melbourne followed by the Astellas facilities in Massachusetts USA Future […]
